History
Multiple myeloma is a disease in which plasma cells produced in the bone marrow inside the bones multiply like cancer. Plasma cells normally make antibodies to fight infection, but when a single type of these cells proliferates excessively, the space where normal blood cells are made shrinks, and abnormal proteins are produced in excess, causing various complications. Historically as well, the understanding of this disease has expanded as a disease that explains the causes of "bones becoming weak (fractures), blood becoming insufficient (anemia), and the kidneys becoming damaged."
Initially, it was recorded as a disease in which, on examination of patients with symptoms such as bone pain, fractures, and severe fatigue, lesions that looked like holes punched in the bone (lytic bone lesions) were seen. Later, as blood testing and protein analysis techniques advanced, it became known that a "monoclonal protein," in which a single antibody component appears in unusually large amounts in the blood or urine, is an important clue to this disease. In other words, not only the visible bone lesions but also the "abnormal protein in the blood" became established as a core feature of multiple myeloma.
There are two major turning points in the history of diagnosis and treatment. The first is the emergence of the concept of catching the disease at an earlier stage. As conditions without symptoms but with a risk of future progression were distinguished, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM), "when to start treatment" became an important question. The second is the advancement of treatment: with the arrival of treatments of a targeted nature such as immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and monoclonal antibodies (mAbs), survival time and quality of life improved greatly.
Recently, in some patients even advanced immunotherapies such as chimeric antigen receptor T-cell (CAR-T) therapy have been used, broadening treatment options. These changes have strengthened the view that "multiple myeloma can be managed like a treatable chronic disease," but at the same time they have made it clearer that management of relapse and long-term complications is important.
Causes
In most cases, it is difficult to pinpoint a single cause of multiple myeloma. It is generally understood that genetic damage accumulates during the process by which plasma cells grow and differentiate, and the disease begins when some of these cells escape control and proliferate. In other words, it is closer to a structure in which several risk factors overlap and raise the probability, rather than "arising immediately because of some cause." Also, having a risk factor does not mean the disease will necessarily develop, and it can develop in people with no clear risk factors.
The best-known risk factor is age. Multiple myeloma is generally found more commonly from middle age onward. In addition, a tendency for it to be slightly more common in men has been reported, and the risk may increase slightly if family members have had similar blood diseases. However, it is appropriate to understand these factors not as information that confirms the cause in an individual, but as "background that can increase the likelihood of occurrence."
Environmental factors such as exposure to certain chemicals and radiation exposure are mentioned, but it is usually difficult to conclude at the individual level that "this exposure is the direct cause." Rather, the realistic message is that instead of blaming oneself by pinning down a cause, it is important to be evaluated early when there are warning signs such as unexplained bone pain, anemia, recurrent infections, or decreased kidney function.
Multiple myeloma often starts from MGUS, regarded as a "preceding stage," with some cases progressing over time. It is easy to understand when explained as a continuous process such as "the stage in which plasma cells begin to make a small amount of abnormal protein (MGUS) → the stage in which the cells gradually increase (SMM) → multiple myeloma causing organ damage."
Genetic Epidemiology
Multiple myeloma is usually not a typical hereditary disease that is "inherited directly" from parents. However, there are studies showing that the risk is somewhat higher if family members have had multiple myeloma, other plasma cell disorders, or certain blood cancers. This may be because there is some genetic predisposition, and it is also possible that environmental factors shared by the family or patterns of immune-related diseases acted together.
The more important "genetics" in this disease are the genetic changes acquired within the cancer cells. Plasma cells are produced as a result of B-cell maturation and go through a process of rearranging genes to make antibodies. If mistakes occur in this process, changes such as translocations, in which part of a chromosome moves to another chromosome, can occur, and genes can act in a direction that makes the cells survive better or proliferate faster.
In multiple myeloma, chromosome/gene test results are often reviewed together to assess risk. Tests such as fluorescence in situ hybridization (FISH) are used to check for specific abnormalities, and the results can affect prognosis and treatment strategy. When understanding genetic epidemiology, it is important to think of "family history" and "genetic changes inside the cancer cells" separately.
At the population level, differences in incidence by race or region have also been reported. Such differences are often influenced not by genetic background alone but also by access to diagnosis, health screening systems, the distribution of comorbidities, environmental exposures, and socioeconomic factors together.
General Epidemiology
Multiple myeloma is a relatively uncommon blood cancer, but the number of patients diagnosed tends to increase with population aging. It is generally diagnosed more often from middle age onward, and because it often begins without symptoms or with nonspecific symptoms (fatigue, mild pain), the time of detection varies greatly from person to person. In addition, multiple myeloma is understood not as "a disease that arises suddenly" but as a spectrum in which some cases progress through precursor stages such as MGUS or SMM.
An epidemiologically important feature is that this disease can affect the blood, bones, kidneys, and immune function at the same time. Therefore, the routes to diagnosis are also varied. Some people are diagnosed in orthopedics because of back pain and fractures, some are found while receiving internal medicine care for anemia, and some are diagnosed while being tested in nephrology because their kidney function has worsened. In other words, if one thinks that it "appears with only one typical symptom," it is easy to miss.
The fact that treatment outcomes are steadily improving is also an important epidemiological point. Compared with the past, drug options have increased and strategies such as hematopoietic stem cell transplantation and maintenance therapy have become more refined, making long-term survival possible. As a result, in some patients multiple myeloma is increasingly "managed long-term like a chronic disease," and long-term follow-up and management of complications (bone health, infection prevention, kidney protection) have emerged as epidemiologically more important issues.
An explanation easy to understand from the general public's perspective is as follows. Multiple myeloma is "a disease in which plasma cells increase," but its effects appear in the form of bones becoming weak, blood becoming insufficient, the kidneys being damaged, and infections becoming frequent.
Pathogenesis
The pathogenesis of multiple myeloma can be summarized as "plasma cells multiply like cancer and make abnormal antibody proteins that damage several organs." Plasma cells are originally cells that make antibodies to fight infection. However, when one type of plasma cell acquires genetic mutations and increases without control, it occupies the bone marrow space and interferes with normal blood cell production. As a result, anemia develops, and white blood cells and normal antibodies decrease so that infections can become frequent.
Another key element is the abnormal protein. Multiple myeloma cells excessively produce one type of antibody or fragments of antibodies (such as light chains) and release them into the blood and urine. These proteins can raise blood viscosity or block the filtration structures of the kidneys, causing decreased kidney function. In some cases, the abnormal protein can also accumulate in tissues and lead to complications such as amyloid light-chain (AL) amyloidosis, which impairs organ function.
The reason bone lesions develop is also central to the pathogenesis. Multiple myeloma cells interact with the bone marrow microenvironment and can change the environment in a direction that activates bone-dissolving cells (osteoclasts) and suppresses the function of bone-forming cells (osteoblasts). As a result, lytic bone lesions develop, bone pain and pathological fractures appear, and hypercalcemia can develop from the calcium released as bone dissolves.
Rather than appearing in its complete form all at once, this disease often progresses in stages, such as MGUS → SMM → multiple myeloma. Treatment becomes necessary when organ damage meeting criteria such as hypercalcemia, renal failure, anemia, and bone lesions (CRAB) or SLiM-CRAB appears. In SLiM-CRAB, S means a bone marrow plasma cell percentage ≥ 60%, Li means abnormal light chains in the serum being 100 times higher than normal, and M means ≥ 1 focal lesion on MRI (each lesion ≥ 5mm).
Symptoms
The symptoms of multiple myeloma are not fixed to one type, but the main axes that are easy for the general public to remember are "bones, blood, kidneys, and infection." One of the most common symptoms is bone pain. Pain may persist especially in areas that bear weight or move a lot, such as the lower back, ribs, and pelvis. When bones weaken and microfractures or compression fractures occur, unlike simple muscle pain, the pain does not heal well over time and can become worse with movement.
The second is fatigue and general weakness. This often results from reduced oxygen delivery due to anemia, and it can appear as everyday activities suddenly becoming difficult or climbing stairs becoming a struggle. The third is recurrent infection. In multiple myeloma, normal antibodies can decrease and immune function can weaken, so infections such as pneumonia, urinary tract infections, and shingles may become frequent or may not heal well.
The fourth is kidney-related symptoms. Kidney damage may have no obvious symptoms and be found first on tests, but it can also appear as symptoms such as changes in urine output, swelling, nausea, and loss of appetite. The fifth is symptoms of hypercalcemia. Thirst and frequent urination, constipation, nausea, confusion, and, in severe cases, decreased consciousness can appear, and this can become a condition requiring emergency evaluation.
Neurological symptoms can also appear. If a nerve is compressed by a spinal lesion or fracture, leg numbness, decreased sensation, and muscle weakness can develop, and if back or lower back pain is accompanied by urinary or bowel dysfunction, spinal cord compression should be suspected. If bone pain persists and anemia, decreased kidney function, proteinuria, recurrent infections, and symptoms of hypercalcemia are seen together, multiple myeloma must be considered in the differential diagnosis.
Signs
Signs are objective findings that medical staff confirm on examination or testing. The most important signs in multiple myeloma are findings of organ damage that fall under CRAB (hyperCalcemia, Renal insufficiency, Anemia, Bone lesions). First, anemia is common. Hemoglobin falls on the complete blood count (CBC), and as a result findings such as pallor and shortness of breath may accompany it. The second is decreased kidney function. Blood tests may show elevated creatinine or a reduced glomerular filtration rate, and urinalysis may confirm proteinuria.
The third is hypercalcemia. When serum calcium rises, symptoms such as dehydration, changes in consciousness, and constipation can appear, and on testing, worsening kidney function may accompany the rise in calcium. The fourth is bone lesions. Imaging may show lytic bone lesions, or vertebral compression fractures or pathological fractures may be confirmed.
One of the key signs of multiple myeloma is an abnormal monoclonal protein. An M protein may be observed on serum protein electrophoresis (SPEP) and urine protein electrophoresis (UPEP), or a monoclonal component may be confirmed on immunofixation (IFE). In addition, a pattern in which one light chain is excessively increased may be seen on the serum free light chain (FLC) test. The presence of a monoclonal protein does not always mean multiple myeloma, as it can also appear in MGUS or other plasma cell disorders, so it is interpreted as "one piece of the diagnostic puzzle."
Signs also appear in terms of immune function. Hypogammaglobulinemia, in which normal immunoglobulins are low, may be observed, and it is linked to the clinical finding of actually recurring infections. Ultimately, these signs are "clues that raise suspicion," and for a definitive diagnosis, the percentage and nature of plasma cells must be confirmed by bone marrow examination, and imaging and protein tests must be integrated to evaluate whether the criteria are met.
Screening
At present, no standard screening test for multiple myeloma for the general public (an early checkup regularly recommended for everyone) has been established. The reasons are clear. First, because its incidence in the overall population is relatively low, the efficiency of across-the-board screening can be poor. Second, even when a monoclonal protein is found, many cases are conditions like MGUS that never progress during a lifetime, so screening can create unnecessary testing and anxiety. Third, it is difficult to accurately detect all multiple myeloma with a single test.
Realistic "screening" is early evaluation based on symptoms and risk situations. When there is unexplained anemia, decreased kidney function, persistent bone pain, recurrent infections, or symptoms suggestive of hypercalcemia, "tests for diagnosis" should be carried out. In particular, multiple myeloma should be considered in the differential diagnosis when a person who has long suffered from chronic low back pain has an unexplained fracture on imaging, or when anemia and decreased kidney function are found at the same time.
For people already diagnosed with MGUS or SMM, it is important to enter a "follow-up program" rather than general screening. Signs of progression must not be missed, with regular protein tests, blood tests, kidney function and calcium evaluation, and imaging if needed. The most practical message for the general public is that multiple myeloma is a disease whose cause must be fully investigated when persistent abnormal signs are present.
Diagnosis
The diagnosis of multiple myeloma is a process of combining several tests to confirm "how much and in what form plasma cells have increased" and "whether organ damage has resulted." The first step is the medical history and examination. The location and pattern of bone pain, weight loss, fatigue, whether infections recur, symptoms of hypercalcemia such as thirst and frequent urination, and neurological symptoms such as numbness or muscle weakness are checked.
The second is basic blood tests. The complete blood count (CBC) checks for anemia, creatinine and the glomerular filtration rate evaluate kidney function, and calcium, albumin, inflammation-related markers, and, if needed, prognostic markers such as lactate dehydrogenase (LDH) and beta-2 microglobulin (β2M) are checked. The third is protein/immune tests: serum protein electrophoresis (SPEP), urine protein electrophoresis (UPEP), immunofixation (IFE), and the serum free light chain (FLC) test confirm the presence and amount of monoclonal protein.
The fourth, and the key to definitive diagnosis, is bone marrow examination. Bone marrow aspiration/biopsy confirms the percentage and morphology of plasma cells, and, if needed, flow cytometry evaluates the immunophenotype of the cells. Chromosome and gene tests (especially FISH) are also used to identify high-risk features. Finally, imaging (low-dose whole-body CT, whole-body MRI, PET-CT) evaluates lytic bone lesions, bone marrow lesions, the risk of spinal cord compression, and other findings.
All of this information is integrated to make the diagnosis according to the SLiM-CRAB criteria. If plasma cell proliferation is confirmed and there is organ damage such as CRAB (hypercalcemia, renal failure, anemia, bone lesions), or there are specific markers (SLiM) indicating that future organ damage is judged to be very imminent, it is classified as multiple myeloma requiring treatment. The key point is that diagnosis is a process of confirming "protein abnormality + bone marrow plasma cells + organ damage/risk" together.
Treatment
The treatment of multiple myeloma differs from patient to patient. Which drug is best is not determined by "stage" alone; it depends on age and general condition, comorbidities (especially kidney function), whether the patient is in a genetic high-risk group, the severity of symptoms, and whether hematopoietic stem cell transplantation is possible. Treatment broadly combines "treatment that suppresses the disease itself" and "supportive care that reduces complications."
Various drug combinations are used as treatment to suppress the disease itself. Typically, combinations of immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and steroids (e.g., dexamethasone) are commonly used, and in many cases a monoclonal antibody (mAb) is added. The goals of treatment are to achieve as deep a remission as possible, delay relapse, and minimize organ damage.
In some patients, autologous stem cell transplantation (ASCT) after high-dose chemotherapy is considered. In cases of relapse or poor response to treatment, the patient is switched to a different class of drugs or a new combination is used. In some situations, advanced immunotherapies such as chimeric antigen receptor T-cell (CAR-T) therapy or bispecific antibodies are discussed.
Supportive care is as important as treatment. It includes bone-protective treatment to reduce bone complications (e.g., bisphosphonates), pain control, fracture prevention and rehabilitation, treatment of hypercalcemia, fluid management and medication adjustment to protect the kidneys, and infection prevention (vaccination and, if needed, prophylactic antibiotics/antivirals). Treatment is not "done once and finished"; long-term management may be needed in the sequence of remission induction, maintenance, and retreatment at relapse.
Prognosis
The prognosis of multiple myeloma has improved greatly compared with the past, but individual differences are still very large. The most important factors that determine prognosis are the risk level of the disease (including genetic features), the degree of organ damage at diagnosis, the response to treatment, and the patient's general condition. In other words, even with the same diagnosis, some people respond well to treatment and remain stable for a long time, while others may relapse quickly or have a course that is difficult to treat.
Staging systems are commonly used when discussing prognosis. The International Staging System (ISS) and its modified versions combine blood test markers (albumin, β2M, LDH, etc.) and genetic risk findings to divide patients into risk groups and are used to plan treatment strategies. This classification is not meant to "predict the future precisely"; it is a tool for deciding treatment intensity and planning follow-up.
Prognosis includes not only survival time but also quality of life. Even if treatment suppresses the disease itself, "actual daily life" improves only when management that restores bone health, protects kidney function, and prevents infections is carried out together. Multiple myeloma can often recur, but as treatment options available even at relapse have increased, it is increasingly common for it to be "managed for a long time through several lines of treatment."
In the long term, treatment side effects also affect prognosis. Problems such as peripheral neuropathy, fatigue, cardiovascular burden, the risk of second cancers, and the risk of chronic infection can remain, so regular checkups are needed. Therefore, when explaining prognosis, it is realistic to discuss "the possibility of achieving remission with treatment" together with "the possibility of relapse and the need for long-term management."
Prevention
No reliable way to completely prevent multiple myeloma is yet known. This is because in most cases there is no clear single cause, and the disease arises as genetic changes accumulate after birth. Therefore, definitive prevention methods such as "eating a certain food prevents it" lack evidence. However, practices that tend to lower risk and behaviors close to early detection are possible.
From an environmental standpoint, reducing exposure to chemicals and unnecessary radiation exposure is desirable for overall health. Because obesity, smoking, and chronic inflammatory states can affect overall cancer risk and health, maintaining basic healthy habits such as regular exercise, a balanced diet, and not smoking is helpful. However, it is difficult to say that this "directly prevents" multiple myeloma, and it is better understood as a recommendation for protecting overall immunity and long-term health.
Secondary prevention after diagnosis is also important. Because the risk of infection can increase with multiple myeloma, it is good to plan vaccinations and to have a safety net for responding quickly if fever or respiratory symptoms develop. For bone health, fall prevention, maintaining muscle strength, pain control and rehabilitation, and receiving bone-protective treatment if needed also help reduce fractures and complications.
The practice closest to prevention is early evaluation and follow-up of high-risk conditions. For people diagnosed with MGUS or SMM, it is important to catch signs of progression early through regular follow-up. When there is a combination of symptoms such as unexplained anemia, persistent bone pain, decreased kidney function, recurrent infections, or suspected hypercalcemia, it is necessary to be evaluated rather than dismissing it as "just getting older." "Complete prevention" is difficult, but reducing conditions that raise risk and being thorough about early evaluation and complication prevention is the realistic method of prevention.